• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Curis, Inc.

NASDAQ:CRIS

$4.60 -$0.06 (-1.29%)

REAL-TIME: Last trade at

Curis Announces Collaborators' Presentation of Erivedge(TM) and Debio 0932 Clinical Data at ASCO Annual Meeting

Curis, Inc. (CRIS) Reports In-Line Q1 EPS

Curis announces collaborator Roche's submission of Erivedge with TGA

Curis to Release First Quarter 2012 Financial Results and Hold Conference Call on May 8, 2012

Curis to Present at the Deutsche Bank Securities 37th Annual Health Care Conference

Curis drug showed encouraging activity in abstracts, says Piper Jaffray

Curis poised to obtain steady royalties from Erivedge, says Roth Capital

Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference

3 New Biotech Buys for Your Portfolio

Curis tops its 10-day MA, resistance is now at $5.01, then at $5.18

Curis Presents Data on PI3K and HDAC Inhibitor CUDC-907 at AACR Annual Meeting 2012

American Association for Cancer Research to host annual meeting

Curis to Present at the 11th Annual Needham Healthcare Conference

Curis added to Focus List at Roth Capital

BMO Capital hosts an analyst Biotchnology/Industry conference call

Curis initiated with an Outperform at BMO Capital

Curis to Present at the Roth 24th Annual OC Growth Stock Conference

Curis to Present at the 32nd Annual Cowen and Company Health Care Conference

Curis to Present at the 2012 RBC Capital Markets' Healthcare Conference

Curis and Debiopharm announce initiation of Phase Ib expansion study of HSP90

Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

Curis initiated with an Overweight at Piper Jaffray

Curis, Inc. (CRIS) Tops Q4 EPS by 2c

Curis reports Q4 EPS 7c vs. consensus 6c

Curis Reports Fourth Quarter and Year-End 2011 Financial Results

Curis to Present at the 14th Annual BIO CEO & Investor Conference

Curis price target raised to $7 from $5 at Summer Street

Curis target raised to $7.50 from $6 at Oppenheimer

Biotech Industry Organization to host a conference

Curis confirms FDA approval for Erivedge

Play TheStreet's FDA Drug-Approval Contest

5 Stocks to Watch Under $5

Curis rises 7.8%

Pre-market Movers For December 22 (BAC, WCAA, YHOO, CRIS, AM, BBBY, VVUS)

Curis Announces Collaborator Roche’s Submission of Marketing Authorization Application for Vismodegib in Advanced Basal Cell Carcinoma

27 Hot Drugs Facing FDA Approval in 2012

Curis initiated with an Outperform at Oppenheimer

Curis to Present at the Oppenheimer & Company’s 22nd Annual Healthcare Conference

In Drug Development, Help Is Crucial

Curis wins Leukemia Lymphoma Society partnership

See More Articles...